MLTX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -4.88. Updated 2026-07-23.
MoonLake Immunotherapeutics (MLTX) Research Hub
MoonLake Immunotherapeutics (MLTX) trades on NASDAQ, CH in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.51 USD (-8.82%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.88, market cap 1.58B. This hub links to the full technical, earnings and options research available for MLTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CH |
| Last close | 12.51 USD (-8.82%) |
| 52-week range | 12.472 USD – 23.29 USD |
| Trend regime | Range |
| 14-day RSI | 9.2 (Oversold) |
| Trailing P/E | -4.88 |
| Market cap | 1.58B |
| Dividend yield | 0.00% |
Available research for MLTX
Covered Call on MLTX: how it works, illustrative setup around the real 12.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MLTX: how it works, illustrative setup around the real 12.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MLTX: how it works, illustrative setup around the real 12.51 USD price, max profit/loss, breakeven and when to use it. Educational.
MLTX technical analysis: range, last 12.51 USD, RSI 9.2, 52w range 12.472 USD–23.29 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MLTX in?
MoonLake Immunotherapeutics (MLTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, CH.
Is MLTX in an uptrend or downtrend?
As of 2026-09-11, MLTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MLTX's trailing P/E ratio?
MLTX's trailing P/E is -4.88, with a market cap of 1.58B. See the earnings research page for full valuation detail.